testicular%20cancer
TESTICULAR CANCER

Testicular cancer is a rare neoplasm that arises from the testis. It commonly presents as a painless testicular mass.

It has high prevalence in young and middle-aged men in the age of 15-40 years old.

It is a highly treatable disease with a high cure rate.

Testicular primary germ cell tumors coming from the malignant transformation of primordial germ cells make up 95% of all testicular cancer.

 

Introduction

  • Most commonly presents as a painless testicular mass
  • Occurs most often in young & middle-aged men, ie age 15-40 yr
  • Highly treatable disease w/ a high cure rate; survival rate in 5 yr is >95%

Pathophysiology

  • Testicular primary germ cell tumors (GCT) coming from the malignant transformation of primordial germ cells make up 95% of all testicular cancer; approximately 5% are extragonadal germ cell tumors (EGGCT) & are found midline in the body, eg cerebrum, mediastinum or retroperitoneum
  • Pathognomonic for GCT is the isochromosome of the short arm of chromosome 12 [i(12p)]

Risk Factors

  • Risk factors include:
    • Cryptorchidism – abdominal cryptorchid testes have a higher risk than inguinal cryptorchid testes
    • Family history of testicular cancer in 1st-degree relatives (father or brother)
    • Personal history of testicular cancer
    • Presence of contralateral tumor or testicular intraepithelial neoplasia (TIN)
    • Klinefelter’s syndrome
    • Testicular dysgenesis
Editor's Recommendations
Most Read Articles
09 Nov 2017
Treatment with fesoterodine shows efficacy in patients with nocturnal urgency secondary to overactive bladder syndrome and low nocturnal bladder capacity with a mismatch between nocturnal urine production and bladder capacity, reports a recent study.
14 Nov 2017
The 5-year survival rates for human papillomavirus (HPV)-associated cancers vary greatly according to age and race, with Caucasians and younger patients tending to have better survival, according to a recent US study.
28 Nov 2017
The use of oral androgen receptor inhibitor enzalutamide may benefit chemotherapy-naïve patients with metastatic castration-resistant prostate cancer and low baseline prostate specific antigen irrespective of disease burden, signifying that targeting the androgen receptor signalling pathway is a therapeutic option in similar patients, suggests a recent study.
22 Nov 2017
Wet nights appear to occur with considerable frequency in children with monosymptomatic nocturnal enuresis and normal maximal voided volumes (MVV), with a nocturnal urine production well below their MWV and even <65 percent of estimated bladder capacity, according to a study.